Appendix

**Table 1**. Defining types of telehealth visits for OUD using VHA stop codes and ICD-10 codes\*

|  |  |  |
| --- | --- | --- |
|  | Clinic Stop Codes | ICD-10 Codes for OUD |
| Video visit | * Secondary stop code: 690, 692, 693, 699, 644, 645, 136, 137, 444, 445, 446, 447, 440, 708, 723,724,490,491, 179,679,648
* CPT modifier= GT, 95
 | F11.1X, F11.2X, F11.9X  |
| Telephone visit | * CPT code=99441, 99442, 99443
* stopcode=545, 527, 338, 103, 147, 148, 169, 178, 181, 182, 199, 216, 221, 229, 324, 325, 326, 424, 425, 428,441,451,452,453,454,462,463,476, 526, 527, 528, 530, 536, 537, 542, 543, 544, 545, 546, 579, 584, 597, 609, 611, 686, 729, 801, 802, 803)
 |
| In-person visit | * The primary stop code, secondary stop code, CPT code and CPT modifier does not include anything from video or phone visit.
 |

\* Modality of buprenorphine treatment visit was defined as a visit with either clinic stop codes or ICD-10 code for that visit type with ICD-10 code for OUD with same provider ID as buprenorphine prescriber

**Table 2**. Interrupted time series analyses of proportion of patients receiving buprenorphine treatment among those with OUD before and after COVID-19 telehealth buprenorphine policy changes

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre-COVID-19 telehealth policy changes 3/2019-2/2020 | Post-Covid-19 telehealth policy changes 3/2020-2/2021  | Post- compared to pre-COVID-19 changes |
|  | Monthly rate1 (slope)  | p-value | Monthly rate1 (slope) | p-value | Rate Change | p-value |
| Proportion of all buprenorphine patients | 0.16 | <0.001 | 0.19 | < 0.001 | 0.03 | 0.12 |
| Proportion of patients initiating buprenorphine | -0.01 | 0.16 | 0.004 | 0.53 | 0.002 | 0.85 |
| Proportion of patients continuing buprenorphine | 0.17 | <0.001 | 0.20 | <0.001 | 0.03 | 0.22 |

1Change per month in the proportion of patients receiving buprenorphine treatment

**Table 3**. Visit modality for buprenorphine treatment visits after COVID-19

|  |  |  |  |
| --- | --- | --- | --- |
|  | Video1 | Phone2 | Total number of patients receiving buprenorphine (also including those with only in-person visits) |
| Urban | 36.6.% (n=5,481) | 45.7% (n=6,842) | 14,984 |
| Rural | 35.1% (n=777) | 46.5% (n=1,029) | 2,213 |

1Defined as patients who received any video visits in the post-COVID year (may have also received phone or in-person visits)

2Defined as patients who received phone visits (may have also received in-person visits but could not have received any video visits)